Koneksa, a New York-based company focused on designing and validating digital biomarkers, raised $45M in Series C funding.
The round was led by AyurMaya with participation from Takeda Ventures and Velosity Capital, as well as existing investors McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital), Spring Mountain Capital and Waterline Ventures. As part of the financing, Karan Takhar, Senior Managing Director at Matrix will join Koneksa’s Board of Directors.
The company, which has raised approximately $65M in gross proceeds from private financings to date, intends to use the funds:
- to expand digital biomarker technology platform,
- to develop the self-service capabilities of its clinical data integration solutions, and
- to extend its scientific team.
Led by Chris Benko, CEO, Koneksa is a patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical measures. The company supports agile decision-making in drug development and market strategy.
As part of the company’s growth, John A. Wagner, M.D., Ph.D., has been appointed as the company’s first Chief Medical Officer (CMO), where he will oversee clinical investment and strategy. With more than 20 years of drug development experience, Dr. Wagner has led more than 150 first-in-human studies and has brought numerous blockbuster programs to market including Januvia (sitagliptin) and Zolinza (vorinostat). Prior to joining Koneksa, he was CMO of Cygnal Therapeutics, and has also held senior leadership roles at Takeda and Merck, a venture partner at Foresite Capital and is Editor-in-Chief of Clinical and Translational Science and an executive committee member of the Foundation for the National Institutes of Health Biomarkers Consortium.
FinSMEs
08/02/2022